Event Coverage

Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new disease-modifying therapies.

Academic and clinical experts convened in New Haven, Connecticut, on October 30, 2025, to discuss the potential of coordinated care and prevention to manage cardio-renal-metabolic (CRM) disease.

Clinicians and health system leaders met in Cleveland, Ohio, on October 23, 2025, to share improvements to value-based care in diabetes and chronic kidney disease.

Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for treating Alzheimer disease and multiple sclerosis.

Experts at an Institute for Value-Based Medicine event held October 14, 2025, in Aurora, Colorado, explored advances in neurology care, cross-specialty collaboration, and strategies to improve access and therapy.

Experts met in Park City, Utah, on October 7, 2025, to discuss how new technologies can help address chronic kidney disease.

Speakers at the Institute for Value-Based Medicine event held September 18, 2025, in Nyack, New York, spoke about methods of managing cardio-renal-metabolic disease.

Payer and health system leaders convened in Pittsburgh, Pennsylvania, on September 9, 2025, to discuss the interconnected health conditions of cardiovascular-kidney-metabolic (CKM) syndrome.

Cardiologists, nephrologists, and payers met in Scottsdale, Arizona, on August 26, 2025, to share insights on how team members can work together, empowered by data, to achieve value-based management of cardio-renal-metabolic syndrome.

Experts in cardiometabolic conditions gathered in Aurora, Colorado, on August 19, 2025, to discuss the methods available to prevent cardiovascular events.

On July 9, 2025, experts from across Providence Health & Services gathered in Garden Grove, California, for in-depth discussions on patient-centered care for chronic diseases.

Emilie Aschenbrenner, PharmD, BCOP, highlights how measurable residual disease (MRD) testing can support value-based care in multiple myeloma by guiding personalized treatment intensity, potentially reducing costs and improving outcomes.

Jason Bergsbaken, PharmD, MBA, BCOP, explains the value of pharmacist involvement in precision molecular tumor boards and end-of-life care discussions, highlighting their role in ensuring evidence-based therapy selection, patient-specific recommendations, and shared decision-making that aligns treatment with individual goals.

Clayton Irvine, PharmD, MBA, MS, discusses strategies to address payer-driven biosimilar and prior authorization challenges through integrated digital solutions, while advocating for flexible, regularly reviewed treatment pathways supported by molecular tumor boards and artificial intelligence to balance standardization with personalized, biomarker-driven oncology care.

Clayton Irvine, PharmD, MBA, MS, explains that leveraging high-quality, real-world data; cross-institutional collaboration; standardized care pathways; advanced technologies; and integrated academic–community oncology partnerships can improve treatment decision-making, reduce financial toxicity, address drug shortages, and optimize infusion center efficiency.

Jason Bergsbaken, PharmD, MBA, BCOP, highlights the operational challenges of value-based oncology care while emphasizing the need to balance standardized treatment pathways with flexibility for personalized, biomarker-driven care.

Jason Bergsbaken, PharmD, MBA, BCOP, highlights the growing role of real-world data in validating or de-implementing therapies, the need for vigilant postapproval outcomes monitoring, and the value of academic–community oncology partnerships.

Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies are transforming multiple myeloma care, with earlier use, expanded community access, and outpatient delivery models offering opportunities to improve value, safety, and equity in treatment.

On April 10, 2025, leaders from Louisiana health systems convened in New Orleans to provide updates on the Healthy State initiative to improve population health in the state.

Discussions at a recent Institute for Value-Based Medicine® event highlighted the interconnected nature of cardio-kidney-metabolic disease and emphasized the need for integrated, patient-centered care.

Cardiologists, primary care physicians, and value-based care leaders convened in Phoenix, Arizona, on November 12, 2024, to share case studies and insights on how to align cardiology with the principles of value-based care, including through the application of digital tools.

Tiffany Meng, PharmD, an oncology pharmacist, UCSF Health, shares how pharmacists can collaborate with physicians to find the most effective and affordable therapies for patients.

Experts at a recent Institute for Value-Based Medicine event emphasized the importance of early intervention, policy innovation, and proactive collaboration to transform the management of kidney disease and optimize patient outcomes.

Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.

At an Institute for Value-Based Medicine® event held in Aurora, Colorado, experts discussed strategies to improve patient outcomes and manage health care costs in neurological diseases.

An IVBM event cohosted by The American Journal of Managed Care focused on Healthy State, a multiyear, multistakeholder commitment to moving Louisiana ahead in America’s Health Rankings.

Clinicians, researchers, and payer experts convened in Aurora, Colorado, on August 13, 2024, for discussions on ensuring that the recent advancements in lipid management are making their way to patients.

At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care®, experts discussed efforts to implement obesity management science into practice.

At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care® and Sutter Health, experts illuminated the current state of cardiometabolic health care and offered a glimpse into the future.

The number of Americans with type 2 diabetes and/or obesity is rising, and the entry of therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists has been revolutionary.